Our leadership

Greg Baker, PhD, is the Director of Business Development for the Technology & Innovation Development Office (TIDO) at Boston Children’s Hospital. Greg’s role at TIDO is to help commercialize technologies developed at Boston Children’s Hospital. Greg works with the licensing team and the faculty at all stages of the innovation life cycle, from conception to the transition to the marketplace. He draws upon his experience in technology commercialization at academic institutions such as Children’s National in Washington D.C. and Children’s Hospital of Philadelphia, as well as business development roles at Novartis and Syngenta. His experience also includes supporting startup companies during their initial formation and with competing for early-stage funding, and he is also a registered patent agent.

Greg’s business experience supplements his scientific training of an undergraduate degree in Microbiology from the University of California, San Diego, and a PhD in Molecular Genetics from Harvard Medical School. Greg joined BCH in February 2021, and he is excited to be part of the TIDO team.

Leslie S. Kean, MD, PhD, is a clinician-scientist with extensive laboratory and clinical expertise in transplantation and translational immunology. She is the Director of Pediatric Stem Cell Transplant at Boston Children’s Hospital and the Dana-Farber Cancer Institute, and is the Stranahan Professor of Pediatrics at Harvard Medical School. She is the Chair of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC).

Dr. Kean’s research program is focused on the immunology of hematopoietic stem cell transplantation and immune tolerance in allo- and auto-immune diseases. The overarching goal of her research is to understand mechanisms underlying immune tolerance, with a specific focus on mixed-chimerism induction for solid organ transplantation, graft-versus-host disease (GvHD), transplant rejection, the immunology of GI auto-immune diseases, and the reconstitution of protective immunity after transplantation. Dr. Kean’s work has led to the creation of multiple novel, MHC-defined non-human primate models of both engraftment and GvHD and to several first-in-disease clinical trials.

Joseph A. Majzoub, MD, attended the University of Michigan Honors College and Stanford University School of Medicine. These were followed by internship, residency, and chief residency at the Peter Bent Brigham Hospital, and a postdoctoral fellowship in endocrinology at the Massachusetts General Hospital and the Massachusetts Institute of Technology. Dr. Majzoub joined the Division of Endocrinology at the Brigham and Women's Hospital in 1981, where he remained until moving to Boston Children’s Hospital in 1989 as Chief of the Division of Endocrinology, a position he held for over 29 years until stepping down in 2018 to become the Vice Chair for Research in the Department of Pediatrics. Dr. Majzoub is the Thomas Morgan Rotch Professor of Pediatrics and Professor of Medicine at Harvard Medical School.

Dr. Majzoub’s research concerns how stress influences health and disease, with a particular interest in diseases of the adrenal axis and obesity. He is the scientific founder of three biotech companies focused in molecular diagnostic, therapeutic, and genetic engineering domains. Dr. Majzoub is a mentor to many medical students, postdoctoral fellows, and faculty throughout the United States, and has received several teaching and mentoring awards from Boston Children's Hospital, Harvard Medical School and the Harvard-MIT Health Sciences Technology Program.

William Slattery is a Partner on the Therapeutics team at Deerfield Management and joined the Firm in 2000. Prior to Deerfield, Mr. Slattery was a senior healthcare analyst for 10 years at Amerindo Investment Advisors, where he oversaw biotechnology investments. He has held various positions in research including those at National Medical Enterprises, Johnson & Johnson, and HMSS.

Mr. Slattery is the Chairman of Gilda’s Club New York City, a non-profit organization supporting cancer patients and their families. He holds an undergraduate degree in Biology and Chemistry from State University of New York at Albany and completed coursework in Immunology at the Graduate School-New Brunswick, Rutgers University.

Nadim Shohdy, Ph.D., is the Chief Operating Officer, Deerfield Discovery and Development and joined the Firm in 2024. Prior to Deerfield, Dr. Shohdy was Vice President, Corporate Development at Hyku Biosciences.  Before Hyku Biosciences, Dr. Shohdy served as Entrepreneur in Residence at RA Ventures, a division of RA Capital Management, during which time he also served as Vice President, Corporate Development at Clear Creek Bio. Prior to these roles, Dr. Shohdy spent 10 years at NYU Langone Health in roles of increasing seniority, including most recently as Associate Dean, Therapeutics Alliances. Dr. Shohdy started his career as a Research Associate at Cold Spring Harbor Laboratory before serving as a Research Analyst, Innovation Fund at the International AIDS Vaccine Initiative. Dr. Shohdy holds a B.S. in Biology from Stony Brook University and a M.A., M.Phil and Ph.D. in Microbiology from Columbia University.